<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837667</url>
  </required_header>
  <id_info>
    <org_study_id>L12-20661</org_study_id>
    <nct_id>NCT01837667</nct_id>
  </id_info>
  <brief_title>Phase I Study of LB-100 With Docetaxel in Solid Tumors</brief_title>
  <official_title>A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lixte Biotechnology Holdings, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lixte Biotechnology Holdings, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of an investigational drug called LB-100 for&#xD;
      Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a&#xD;
      small molecule that in laboratory and animal studies has shown activity when used by itself&#xD;
      or together with drugs approved to treat some types of cancer (chemotherapeutic agents).&#xD;
      Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of&#xD;
      the trade names for docetaxel is TaxotereÂ®. The study is in 2 parts. Part 1: Patients will&#xD;
      receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and&#xD;
      docetaxel. This is the first study where LB-100 for Injection will be used in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.</measure>
    <time_frame>Starting from date of first dose up to 30 days after last dose.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Tumors</condition>
  <condition>Neoplasms</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>LB-100 for Injection and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB-100 for Injection</intervention_name>
    <description>Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.</description>
    <arm_group_label>LB-100 for Injection and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.</description>
    <arm_group_label>LB-100 for Injection and Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Part 1 only: Patients with histologically or cytologically proven progressive or&#xD;
             metastatic solid tumors who have failed standard treatment and have no other effective&#xD;
             treatment available.&#xD;
&#xD;
             Part 2 only: Patients with histologically or cytologically proven progressive or&#xD;
             metastatic solid tumors who have failed standard treatment and have no other effective&#xD;
             treatment available, or docetaxel-naive patients who have failed standard treatment&#xD;
             and have tumors for which a docetaxel-based regimen would be appropriate.&#xD;
&#xD;
          2. Part 2 only: Patients must be docetaxel-naive.&#xD;
&#xD;
          3. Patients must have a life expectancy of at least 12 weeks.&#xD;
&#xD;
          4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 or 1.&#xD;
&#xD;
          5. Patients must be men and women &gt;= 18 years of age.&#xD;
&#xD;
          6. Patients must have recovered from all acute adverse effects (excluding alopecia) of&#xD;
             prior therapies to baseline or &lt;= grade 1 prior to study entry.&#xD;
&#xD;
          7. Patients must have adequate bone marrow function, defined as an absolute neutrophil&#xD;
             count &gt;= 1.5 x 10^9/L and a platelet count &gt;= 100 x 10^9/L.&#xD;
&#xD;
          8. Patients must have adequate renal function, defined as serum creatinine &lt;= 1.5 x upper&#xD;
             limit of normal (ULN) for the institution or a calculated creatinine clearance&#xD;
             [Cockcroft-Gault method] must be &gt;= 60 mL/min/1.73 m^2).&#xD;
&#xD;
          9. Patients must have adequate hepatic function, defined as:&#xD;
&#xD;
               -  Part 1 only: plasma total bilirubin &lt;= 1.5 mg/dL, alanine transaminase (ALT) and&#xD;
                  aspartate transaminase (AST) &lt;= 2.5 X ULN.&#xD;
&#xD;
               -  Part 2 only: plasma total bilirubin &lt;= ULN; ALT and/or AST &lt;= 1.5 X ULN&#xD;
                  concomitant with alkaline phosphatase &lt;= 2.5 X ULN.&#xD;
&#xD;
         10. Female patients of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test result at time of pre-treatment screening.&#xD;
&#xD;
         11. Patients with reproductive potential must agree to use at least one form of barrier&#xD;
             contraception prior to study entry and for up to 30 days beyond the last&#xD;
             administration of study drug.&#xD;
&#xD;
         12. Patients must be capable of providing informed consent and must be willing to provide&#xD;
             written informed consent prior to the start of any study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients may not have had prior chemotherapy, radiotherapy, hormonal therapy, or&#xD;
             biologic therapy in the 4 weeks prior to study entry with the exception of mitomycin C&#xD;
             or nitrosoureas, for which patients must be 6 weeks from prior treatment. For patients&#xD;
             who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days,&#xD;
             whichever is shorter) must have passed prior to enrollment in the study.&#xD;
&#xD;
          2. Part 2 only: Patients may not have had prior treatment with docetaxel.&#xD;
&#xD;
          3. Part 2 only: Patients with plasma total bilirubin &gt; ULN; ALT and/or AST &gt; 1.5 X ULN&#xD;
             concomitant with alkaline phosphatase &gt; 2.5 X ULN.&#xD;
&#xD;
          4. Patients may not have any concomitant condition that could compromise the objectives&#xD;
             of this study and the patients' compliance and ability to tolerate this therapy and&#xD;
             complete at least 2 cycles of therapy, including, but not limited to the following:&#xD;
&#xD;
               -  Congestive heart failure or uncontrolled angina pectoris, previous history of&#xD;
                  myocardial infarction within 1 year from study entry, uncontrolled hypertension,&#xD;
                  or dysrhythmias.&#xD;
&#xD;
               -  Active infection.&#xD;
&#xD;
               -  Unstable diabetes mellitus.&#xD;
&#xD;
               -  Psychiatric disorder that may interfere with consent and/or protocol compliance.&#xD;
&#xD;
               -  Uncontrolled seizure activity.&#xD;
&#xD;
               -  Prior history of inflammatory bowel disease.&#xD;
&#xD;
               -  Prior history of pulmonary fibrosis.&#xD;
&#xD;
               -  Prior history of cardiomyopathy.&#xD;
&#xD;
          5. Patients with a history of central nervous system (CNS) malignancy.&#xD;
&#xD;
          6. Pregnant or breastfeeding women.&#xD;
&#xD;
          7. Patients with another malignancy in the past 3 years except: curatively treated&#xD;
             non-melanoma skin cancer, or carcinoma in situ (either cervix or breast) that does not&#xD;
             require further treatment.&#xD;
&#xD;
          8. Patients with known active human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV), or hepatitis C virus (HCV) infection.&#xD;
&#xD;
          9. Part 2 only: Patients with a history of severe hypersensitivity reaction to drugs&#xD;
             formulated with polysorbate 80 (for example, drugs formulated with polysorbate 80&#xD;
             include, but are not limited to: Aranesp, Eprex, Cordarone, some vaccines).&#xD;
&#xD;
         10. Part 2 only: Patients with &gt;= grade 2 peripheral neuropathy.&#xD;
&#xD;
         11. Patients with an underlying diagnosis or disease state associated with an increased&#xD;
             risk of bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Chung, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope National Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Mansfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fadi Braiteh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Cancer Centers of Nevada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Becerra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology - Baylor Charles A Sammons Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Richards, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology - Tyler</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.</citation>
    <PMID>28039265</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>LB100</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>publication</doc_type>
      <doc_url>http://clincancerres.aacrjournals.org/cgi/content/abstract/1078-0432.CCR-16-2299</doc_url>
      <doc_comment>&quot;Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors&quot; has been published by Clinical Cancer Research</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

